FLSM
REPL icon

Frazier Life Sciences Management’s Replimune Group REPL Stock Holding History

Frazier Life Sciences Management’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-386,762
Closed -$6.62M – 54
2023
Q3 		$6.62M Hold
386,762
– – 0.44% 38
2023
Q2 		$8.98M Sell
386,762
-300,000
-44% -$5.86M 0.54% 33
2023
Q1 		$12.1M Sell
686,762
-244,798
-26% -$5.82M 0.88% 28
2022
Q4 		$25.3M Buy
931,560
+125,293
+16% +$2.6M 1.58% 17
2022
Q3 		$13.9M Hold
806,267
– – 1.07% 23
2022
Q2 		$14.1M Buy
806,267
+89,505
+12% +$1.47M 1.33% 21
2022
Q1 		$12.2M Buy
+716,762
New +$13.5M 1.04% 31

Other funds holding REPL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Frazier Life Sciences Management's REPL Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Replimune Group (REPL) in Q4 2023, closing a stake of 386,762 shares — an estimated $6.62M sold.

Frazier Life Sciences Management first reported a position in REPL in Q1 2022 and held it in 7 quarters. The position peaked at $25.3M in Q4 2022. 140 funds tracked by Wall St. Rank hold REPL as of Q4 2023.

  • Frazier Life Sciences Management reported no remaining Replimune Group position as of Q4 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 386,762 Replimune Group shares in Q4 2023, an estimated $6.62M.
  • Frazier Life Sciences Management first reported a position in Replimune Group in Q1 2022 and held it in 7 quarters.
  • Frazier Life Sciences Management's Replimune Group position peaked at $25.3M in Q4 2022.
  • 140 funds tracked by Wall St. Rank held Replimune Group as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.